OncoHost Develops Predictive Biomarker for irAEs in Non-Small Cell Lung Cancer

OncoHost has successfully developed a proteomics-based predictive biomarker for immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC). OncoHost’s predictive biomarker offers a game-changing solution to this complex challenge. By accurately predicting the risk of irAEs in NSCLC patients before commencing treatment, it empowers healthcare professionals to develop personalized management plans and strategies for risk reduction. These results have the potential to enhance the overall quality of cancer care for patients worldwide.

Lung Cancers Today spoke with Dr. Ofer Sharon, CEO of OncoHost, to discuss the lack of dependable pre-treatment biomarkers for predicting irAE development and how OncoHost is spearheading the efforts to address this issue.